The Collegium Internationale Neuro-Psycho-pharmacologicum (CINP).

The CINP is an international association registered and domiciled in Zurich, Switzerland under the name CINP Collegium Internationale Neuro-Psychopharmacologicum according to section 60 et seq. of the Swiss Civil Code.

The CINP Central Office is domiciled in:

Glenfinnan Suite
Braeview House
9/11 Braeview Place
East Kilbride
G74 3XH
Scotland, UK

Email: CINP @ glasconf.demon.co.uk
Tel: + 44 1355 244930
Fax: + 44 1355 249959

www.cinp.org

The CINP is a global organisation dedicated to Neuropsychopharmacology. It is a membership organisation with widespread support from all over the world and its major congresses have taken place all over the world. Furthermore it has regional groups which are active all over the world. These groups organise regional meetings, workshops and other educational activities and help support psychopharmacology in their regions.

The CINP mission is to encourage and promote the international scientific study, teaching and application of Neuropsychopharmacology. The CINP achieves these objectives by organization of meetings, consultation to others and development of training programs. It also provides consultation for the better evaluation of all aspects of development and usage of neuropsychiatric drugs, including their biochemistry, pharmacology, safety and therapeutic efficacy. Through these activities the CINP seeks to improve and advance research activities that are intended to lead to improved patient care.

The CINP aims to promote research, education and clinical care in Neuropsychopharmacology world-wide by:

a) Fostering cross-fertilization of scientific knowledge among clinical and preclinical scientists as well as clinicians from relevant disciplines.

b) Defining and articulating clinical methods for the proper study and application of interventions to treat and prevent neuropsychiatric and brain disorders.

c) Developing consensus from scientific and medical data in order to recommend scientific and regulatory policies to improve the well-being and health of individuals with neuropsychiatric disorders in diverse and culturally distinct societies world-wide.

The CINP has an official journal, the International Journal of Neuropsychopharmacology. This has become one of the essential journals in CINP’s field of research and it continues to grow in both size and importance.

For the accomplishment of its purpose the CINP disposes of the membership dues and the financial or other contributions of third parties.

CINP membership.

According to the CINP Statues and By-Laws (annex 2) members of the Association can be natural persons and legal entities as well as corporations under public law which are interested and active in the field of Neuropsychopharmacology.

The CINP has the several classes of individual members: Founding Members, Members, Fellows, Emeritus Fellows and Honorary Fellows. Additional classes of membership are: Supporting Members (Patron, Benefactor, Sponsor and Contributor), Corporate Members (Institutions or corporate organisations who contribute to the financial support of the CINP) and Members of Affiliated Associations.

CINP individual members may be employed at Universities and Academic Institutions, health care facilities, foundations and similar corporations and also at research facilities in pharmaceutical and other companies, sharing the goals of the College.

The present Code of Conduct applies to all members of all classes. Each member is responsible for his or her own acts of commission or omission and shall not be able to morally or legally bind other members of the CINP without their expressed consent.

Scope of the Code of Conduct.

The CINP recognises that there is a wide range of points of view on the issue of relationships between individual scientists and other professionals and commercial organisations, primarily the pharmaceutical industry.

Financial and other dualities and conflicts of interests may arise in many different contexts

in the activities of the CINP and its members. The purpose of the present document is to help identify them and to provide guidelines to handle them.

This document is intended to provide guidance of good practice for CINP members in matters involving receiving and providing funding for activities concerning CINP activities. The goal is to ensure that CINP members achieve probity and transparency while ensuring that their judgement is not inappropriately influenced by commercial principles.

CINP members are bound by the codes of conduct of their national authorities and associations even when they are not exclusively in the field of Neuropsychopharmacology. In case of the rules are breached the CINP may also take action based on the enforcement provision of this Code of Conduct.

Primary values.

CINP members should avoid accepting or giving incentives that might compromise the independence of their scientific and professional judgement and practice.

CINP members need to recognise that although commercial organisations (and their representatives) might have similar goals to their own, they primarily must have responsibilities towards their shareholders.

CINP members should always behave on the basis that their ultimate responsibility is towards science and care of patients.

CINP members should aim for full public disclosure and transparency with regard to competing interests in research and clinical practice.

Definition of conflict of interest.

“A conflict between private interests and official responsibilities of a person in a position of trust” (Webster Dictionary).

An interest is a commitment, goal or value arising out of a social relationship or practice. Dualities and conflicts of interest occur when there are  mismatches between duties or preferred courses of action in relationships based on trust, reliance or dependence.

Conflicting interests and conflicts of interest are not the same. The former occur in any situation where competing matter are assumed to be legitimate; they are a duality of interest. Conflicts of interest, on the other hand, are characterized by individual occupying dual roles which should not be performed simultaneously.

A duality of interest arises when two or more interests co-exist. A duality becomes a conflict of interest if the interests are contradictory and may induce a psychiatrist or researcher to act to favour one interest for personal gain.

Members of CINP could have dualities of interest because of interactions with a pharmaceutical company.  For example, when a psychiatrist or researcher has an interest in their primary responsibility (to their patients or to their research, or both) and to their interaction with a company. This may be even more pronounced when, being employed by a pharmaceutical company, an individual seeks to encourage the use of particular drugs or by a health insurance companies or health care (public or private) system which seek to limit the prescription of drugs for financial reasons. Duality of interest does not, however imply conflict of interest in which competing obligations result in the compromise of one's primary responsibilities. A conflict of interest exists when a professional is influenced by a secondary interest such as financial gain. The notion of “conflict of interests” does not imply by itself an immoral behaviour. Conflicts may arise structurally, out of the facts and not from fraudulent motivations. Furthermore, neither dualities nor conflicts in themselves inevitably cause harm; it is the ambiguity about goals and values and the possibility for harm that arouse concern.

The potentially harmful effects that conflicting interests can have on scientific matters are not exclusively financial. Conflicting schools of thought, sociopolitical positions, personal rivalries and beliefs, could lead to potential negative effects on professional relations and the design, interpretation, presentation, and publication of research results

 

General principles.

The effective management of conflict of interest lies in their identification, their open declaration and developing appropriate structures to deal with declared conflicts. The following principles should be considered:

1.      Individuals must declare dualities of interest, whether financial or non-financial. The conflict of interest may not be obvious, but as this can not be exclusively judged by the presenter, that is why dualities of interest should be declared.

2.      Declaring a conflict of interest in no way implies that the individual has actually been influenced by his or her secondary interest. It is intended to make secondary financial interests more transparent and to allow others to judge for themselves the potential for the individual having been thus influenced.

3.       The declaration must be considered, evaluated and then ruled upon by the pertinent committee or body of the CINP so that,

4.      an judgement can be made concerning whether the dualities constitute a potential or actual conflict;

5.      If a conflict of interests is present or likely, practical strategies are devised to deal with the conflicting interests;

6.      The decisions and practical outcomes are communicated to the affected constituency.

Financial and other thresholds.

Significant risk of conflict of interest  for a clinician or researcher may occur in the following situations:

• being an employee of a private firm,
• holding stocks of a firm related to the field of research,
• owning or being named as an inventor on a patent directly related to the research work,
• being a regular consultant or in the board of directors of a firm.

Honoraria, donation and grants should be reasonable and balanced with the purpose of the contribution.

Honoraria to attend CINP meetings are not acceptable.

Occasional consultancies or refunds would not be a source of substantial conflict of interest.

REGULAR Members Responsibilities

For the purposes of this document Regular Members refers to all the members of CINP with the exception of Supporting and Corporate members.

Donations.

CINP members are allowed to receive offerings provided that their purpose is genuinely educational or dedicated to research. References to the donor organisation should be indicated by no more than the company’s name and/or logo. The CINP recommends that valuable gifts should not be accepted specially if they consist of cash or other financial benefits personally to individual CINP members.

If a College member decides to accept a valuable offering such as an item of equipment or other form of similar contributions from a commercial organisation, the donation should be declared according to national regulations and they should be included in the appropriate disclosure of conflict interest at CINP activities.

Attendance and participation at company-organised meetings

CINP members should only agree to participate in company-organised meetings (as speakers or attendees) if they are satisfied that the meetings has a genuinely educational purpose or to provide rigorous and independent reviews of research data required for drug registration by national authorities.

Hospitality must be secondary to the purpose of the meeting. The level of travel and accommodation facilities and of hospitality offered must be reasonable. It is not acceptable for company-organised meetings to fund spouses and family members not participating in the scientific and College activities of the meeting.

Honoraria for speakers should be declared according to the national association or local employer’s procedures.

CINP members speaking at these meetings should make clear the extent to which their presentation is based on their own original work, their own review of the evidence or on information supplied by the commercial organisation.

CINP members should not exclusively rely only on these events for the purposes of Continuing Professional Development.

Sponsored attendance at regional, national or international scientific meetings.

The meeting must be primary scientific and/or educational and not merely an occasion to engage in travel. Attendance should be free of commercial pressure.

Sponsorship for accompanying persons not participating in the scientific and College activities of the meeting is not acceptable.

CINP members accepting such sponsorship must declare any resultant conflict of interest to meeting organisers and at the beginning of their presentation.

Consultancy, provision of expert opinions and policy advice

All salaried scientists, professionals, employees of trusts, universities or similar organisations should submit to local rules or laws when engaging in such activities.

Declaration of financial conflicts of interest.

All speakers at CINP meetings are asked to declare any financial conflicts of interests that they might have relating to their presentations.

Anyone who presents at a CINP meeting is asked to sign a declaration and, if a conflict of interest exists, to make a brief oral statement and/or present a slide to this effect at the beginning of his or her presentation.

Meeting organizers will provide speakers with forms for the declaration of possible conflicts of interest (annex III), which should be completed and then handed back to the Organizing Committee.

Relationships between scientists undertaking research and commercial organisations.

The CINP is concerned with the fact that researchers could be influenced by commercial goals, or that it may be misperceived to be so influenced.

In order to avoid the reality and/or the perception of this problem, a full declaration of relationships with commercial organisations and a fully informed consent by participants in research are obligatory.

Clinical research.

The CINP encourages commercially funded trials initiated by the investigator, and  researchers benefiting from the resulting intellectual property where appropriate.

All clinical trials should be registered in a public trials registry and research ethics committee approval is mandatory. Payments for research need to be open and transparent.

Investigators participating in research financed by a commercial company should ensure that patients included in the study have received a full explanation of the research procedure and given written agreement.

If the research is funded by a pharmaceutical or other commercial company, then the company must indemnify patients or healthy volunteers for any harm that might arise as a result of participation where such research has been carried out in accordance with previously agreed protocol. In all other cases indemnity is the responsibility of the investigator or the employer.

Study investigators should have access to all data collected for any study for which they are responsible. If data for jointly authored publications are analysed by the commercial organisation, full access to the raw data and analyses must be available to the participating investigators.

Participating investigators should be free to publish valid findings arising from studies funded by pharmaceutical or other commercial organisations, even if these are not supportive of the company’s product. The involvement of the pharmaceutical company or commercial organisation should be acknowledged in any such publication.

Clinical Registries and Disclosure of Data in a Timely Manner

The CINP expects funding sources of research, specially its Corporate Members and Supporters to remain in compliance with the highest ethical standards regarding the evolving issue of making clinical trial information publicly available. CINP Corporate Members and Supporters are expected to firmly comply with CINP guidelines on the registration and reporting of the results of clinical trials.

Authorship

The CINP wishes to endorse the International Committee of Medical Journal Editors (ICMJE) guidelines for authorship and therefore:

The nature of work undertaken by participating investigators and the nature and extent of the pharmaceutical company’s or commercial organisation’s involvement should be explicit in any jointly authored scientific paper.

Honoraria or other support received for other authorial work such as review articles should be made explicit.

Investigators should not agree to ‘author’ articles that have been ghost-written for them. Professional writing support is, however, acceptable if the nature of the work undertaken is explicit and formally declared in the publication.

Corporate Members and supporters Roles and Responsibilities

The CINP values the contributions of the Corporate Members and Supporters to its scientific and professional activities. The CINP expects from its Corporate Members and Supporters the highest ethical standards in relationship to the areas of conflict of interest, anti-trust, proprietary information, anti-kickback, compliance with public clinical registries, and participation in the CINP activities.

The goals of the CINP in its relationships with Corporate Members and Supporters are to:

1.       Enable and encourage Corporate Members and Supporters to contribute to the scientific and professional exchange of knowledge within the College.

2.       Facilitate scientific collaboration between CINP Corporate Members and Supporters, government, and academia with the goal of advancing the mission of the College.

3.       Promote excellence in the scientific enterprise within CINP Corporate Members and Supporters through the interactions of Supporting scientists and scientists from Corporate Members with the rest of CINP members.

4.       Inspire confidence in the public and scientific community at large that scientific research presented at CINP meetings or available in CINP publications meets the highest ethical standards.  This includes research supported by pharmaceutical companies, including research done in collaboration with academic institutions, academic investigators and/or government.

5.       Secure appropriate levels of unrestricted funding through supporting corporation fees to allow the College to carry out the programs and activities necessary to achieve its mission.

6.       Manage the relationship between the College and its Corporate Members and Supporters in such a way that assures the rest of College members, the Corporate Members and Supporters management, and the public at large that any real or perceived conflict of interest are either eliminated or appropriately managed.

The CINP encourages its Corporate Members and Supporters to send their best scientists to the CINP meetings and to submit proposals for scientific presentations.

The CINP also encourages individual scientists from its Corporate Members and Supporters to seek regular membership, with the understanding that they will have the same rights and responsibilities as other members of the College.

The CINP  only allows its Corporate Members and Supporters to use the meetings and publications and in general any kind of activity for marketing or commercial purposes when these are in accordance with this Code of Conduct.

Corporate Members and Supporters invited to serve as ad hoc members of committees or task force and collaborate in CINP activities where their input and advice would be helpful, provided that the rules of the present Code of Conduct are strictly observed.

Participation in the CINP Scientific Meetings

The CINP encourages Corporate Members and Supporters to fully participate in the scientific meeting of the College. Data presented at the annual meeting should reflect original research findings (both negative and positive) reported or made available in a timely fashion, fully and honestly, both in the professional literature and in presentations at scientific meetings.

The Corporate Members and Supporters should be aware that the CINP scientific meetings are dedicated to furthering the exchange of scientific knowledge in the field of Neuropsychopharmacology. Furthermore, Corporate Members and Supporters and their representatives must refrain from organizing competing activities that take meeting attendees away from official and scientific sessions or other College activities and detract from the scientific interaction at the meeting.

Any representative of CINP Corporate Members shall ensure that their participation in CINP has received all approvals that may be required by their employer.

If there are questions about whether or not a particular activity is unethical, the Supporting Member or the Corporate Member Representative shall take the issue to the CINP Corporate Membership Committee and to his or her company for advice.

Conflicts of Interest

The primary mission of the CINP is to advance scientific knowledge and to permit exchange of this knowledge uncontaminated by commercial purpose. CINP Corporate Members and Supporters and their employees, whether they are CINP members or not, must commit to supporting the CINP mission free of commercial bias. The CINP expects that:

1.      If a CINP Member employee of a Corporate Member or Supporter is in a position to participate in CINP scientific discussions that have implications for the commercial interests of his or her employer, he or she should either:

a.    Not participate in those discussions if he or she cannot provide independent and unbiased scientific contributions to the issue; or

b.    If he or she can provide independent and unbiased scientific contributions to the issue, she or he should fully disclose the existence of the potential conflict of interest.

2.      Disclosure of potential conflict of interest should be made not only to other CINP collaborators, but also to the public as a part of any communication or publication of the collaboration.

3.      Supporting Members or representatives from Corporate Members will act to avoid the appearance of impropriety, even when they believe there is no potential for a conflict of interest. The above two options should be considered in each instance. 

4.      Disclosure of possible conflicts of interest for articles should be included in the transmittal letter at the time the article is submitted.  For presentations, potential conflicts of interest should be specified by the presenter. All presentations given by CINP members must disclose any pharmaceutical grant support and whether or not there has been any offer or acceptance of an honoraria or consulting fee. 

5.      Any and all relationships that may be perceived as a conflict of interest must be transparent to the public. 

Given that scientific discussions could impact commercial or marketing issues, these individuals should be familiar with applicable anti-trust regulations and should avoid discussions that could result in anti-trust violations.

Proprietary Information 

CINP fosters the exchange of scientific information among its members and meeting attendees, though, there are limitations on information that can be shared. Supporting Members or employees of Corporate Members with commercial interests are obligated to keep proprietary company information (e.g., undisclosed research data; development plans; trade secrets) confidential.

Payments to CINP and its Members.  

Supporting and Corporate members may provide a grant to a scientist or professional who is a CINP member. It must be clear and documented that such grants support legitimate scientific or educational purposes, are based on objective criteria, and do not represent payment for influence or favourable treatment of the Supporting or Corporate member or its products. Any and all payments, reimbursements and other financial arrangements between a CINP Supporting or Corporate Member and CINP must be documented and approved both by member and the CINP, and subject to a possible auditing process.

Relationship between CINP activities, the pharmaceutical industry and other commercial organisations

This section concerns all relevant CINP Officers who are involved in College activities. A ‘relevant College Officer’ is an honorary officer, elected or appointed, namely: members of the Executive Committee, the Council, the Counsel, the different Committees (Nominating Committee, Credentials and Membership Committee, Publications Committee, International Scientific Program Committee, Congress Organising Committee, Finance and Budget Committee, Fellowship and Awards Committee, Corresponding Organizations Committee, Constitution and By-Laws Committee, History Committee, Education Committee, Corporate Membership Committee, Presidents Committee and Ethics and other committees) and task Forces.

Activities organised in the name of the CINP and/or using the College logo should preceded by a full declaration of relationships with commercial organisations and advertising must fit with the College’s strategic aims.

As a general rule, grants can be accepted from commercial organisations to support CINP activities provided that they are unrestricted and that the donor does not have any influence on the content nor dissemination. The CINP is committed to reasonably limit substance and appearance of commercialism at scientific meetings, in publications and on the website and other initiatives.

Approaches to commercial organisations

Initial approaches to or from potential advertisers, should be negotiated only by the appropriate Officer(s) of the College. Every effort must be made to attract a wide range of advertisers – including government agencies, charitable trusts and foundations, as well as commercial organisations – so that there is no dependence on any one source.

Meetings, conferences and educational events

Unrestricted educational grants can be accepted from commercial organisations to support CINP educational activities. The donor should not have control over the use of the gift or the content of the educational activity. Income from pharmaceutical companies and other commercial organisations not conforming to the above can only be accepted for exhibition stands and for inserts in delegate packs.

The Congress Organising Committee will approve the announcement for sponsorship prepared by the Professional Congress Organiser (PCO) and will supervise the bidding process. The Congress Organising Committee will create an Industrial Liaison Committee. This committee will comprise company representatives, member of the Local Organising Committee and the representative of CINP. This committee will be responsible for the planning of amounts of sponsorship to the Congress and should provide guidelines for the appropriate expenditures.

The Exhibition is the commercial place of the Congress. Therefore, the Industrial Liaison Committee will set up specific rules for activities outside of the exhibition area and develop alternative ways to acknowledge support for meeting infrastructure, establishing alternative methods for giving recognition for financial support, to be approved by the Congress Organising Committee. The Industrial Liaison Committee will take steps to minimize allowed promotional items to reduce the spill-over of branding outside the exhibition hall, to limit sponsored hospitality activities beyond what is reasonable and develop a pool of support for activities such as travel awards and fellowships.

The CINP should retain control of the title, educational and/or scientific content and the level of hospitality and advertising.

Awards and fellowships.

The CINP currently has Awards sponsored by pharmaceutical companies. These are given in the form of unrestricted educational grants. The name of these companies is in some cases incorporated into the award either directly or indirectly.

Research undertaken on behalf of the CINP.

Any CINP research funded by pharmaceutical companies or commercial organisations should clearly acknowledgement of the company’s involvement.

The methodology, results and conclusions of commercially-funded research must not be influenced by the sponsor, and the sole purpose of the funding should be to promote genuine scientific research.

The CINP shall retain control of the title, educational and/or scientific content, and results of any commercially funded research. This commercial funding should not affect the outcome or the dissemination of the outcome of any research. Individual products should not be promoted.

Public education activities

Sponsorship from organisations that would have no direct gain from association with the CINP may be used to produce and facilitate the dissemination of information on neuro-psychopharmacology for the general public, teaching packages and other publications. All fully or partially sponsored educational activities must disclose the sponsor.

Scientific publications

Authors of papers published in CINP journals must declare any conflicts of interest. Commercial organisations may advertise in scientific publications. The level of such sponsorship should be determined by the Editor.

Newsletters

Sponsorship may be obtained to support the production and circulation of newsletters for any of the CINP bodies but the advice and authorisation of the Executive Committee should be sought. Details of any proposed advertisements must be included in the budget of the newsletter. Modest acknowledgement of any sponsorship may be made in the newsletter.

Website

The College website should not be sponsored. Where electronic versions of sponsored materials (e.g. campaigns and public education information) appear on the CINP website, then the original sponsor may be credited.

Links to sponsored educational sites are permitted but there should be no direct link to commercial sponsors.

Uses of advertising

The principal use of selling advertising is to improve the quality of educational or scientific activities. This may include research, meetings and conferences, awards and fellowships, public education materials, newsletters and scientific publications.

All advertising items should be negotiated to represent the best interests of the CINP. College Officers and/or staff should remain impartial.

Any advertising should not directly promote a particular product, with the exception of advertising in CINP journals or on exhibition stands.

Commercial advertising may not be used to support the publication or distribution of guidance on good practice, or consensus statements such as clinical guidance.

Ownership and acknowledgement

Commercial organisations, including pharmaceutical companies, support medical educational activities and other CINP activities. In such cases the College retains control of the title, the content, the selection or approval of speakers of any event or product and the level of advertising. Some proportionate and discreet acknowledgement of the commercial organisations can be given.

Acceptance of advertising by the CINP does not imply an endorsement of the commercial organisation’s products.

Declaration of competing interests

Speakers and discussants at College meetings must declare any personal association with any potential sponsor which could be construed as a potential conflict of interest.

Authors of CINP publications must declare any personal interest or association with organisations relevant to the subject of the publication or article.

Candidates for honorary, elected or appointed posts of the CINP are requested to present to the Executive Committee a declaration of possible conflicts of interest, prior to the election or designation.

Register of Officers’ interests.

The CINP will set up a register of potential conflict of interests for Officers.

Enforcement

This code of conduct is the standard for behaviour that the CINP expects of its members. Any CINP member who believes that any other member has violated this code of conduct may bring that matter to the attention of the CINP Executive Committee who will submit it immediately to the Ethics Committee. The Ethics Committee is empowered to investigate the matter, and will send a report back to the Executive Committee. If upon investigation the Ethics Committee considers that the CINP member is in violation of this code of conduct, the Executive Committee will bring that matter to Council.  Council will then have the responsibility to conduct any additional investigation it may deem suitable and to determine any sanction it may deem appropriate, up to and including banning membership, according to the Statues and the By-Laws of the CINP.

Revision.

This Code of Conduct will be revised every three years or whenever the CINP President finds appropriate.

ANNEX I: Task force

Juan J. López-Ibor (Spain, chair) jli(at)lopez-ibor(dot)com

David Copolov (Australia) david.copolov@adm.monash.edu.au

Robin Emsley (South Africa) RAE@sun.ac.za

Lars Farde (Sweden) Lars.Farde@ki.se

Giovanni Fava (Italy)   giovanniandrea.fava@unibo.it  

Alan Frazer (USA) FRAZER@uthscsa.edu

Guy Goodwin (UK) Guy.Goodwin@psych.ox.ac.uk

Atul Pande (USA) atul.c.pande@gsk.com

Siu Wa (SW) Tang (Hong Kong) swtang@uci.edu

 

Annex III: Declaration of Conflicts of Interest Form

MEETING:

PRESENTER:

TITLE OF PRESENTATION:

Have you at any time accepted the following from an organisation which might be perceived in any way to gain or lose from the content of your presentation.

[ ] Funds for a member of staff?                     [ ] Fees for consultancy?

[ ] Funds for research?                                    [ ] A fee for speaking at a symposium?

[ ] Sponsorship for attending a meeting?        [ ] Any other form (please specify)

…………………………………………………………………………………..

Have you at any time been employed by an organisation which might in any way gain or lose from the content of your presentation (possibly relevant organisations include pharmaceutical companies, independent healthcare organisations, and the Health Administration Branch)?

[ ] No               [ ] Yes

Do you hold stocks or shares in a significant proportion in an organisation which might in any way gain or lose from the content of your presentation?

[ ] No               [ ] Yes

Do you have any other competing financial interests?

[ ] No               [ ] Yes (please specify below)

............................................................................................................................

Does your partner or any other close family member have competing interests which should be declared?

[ ] No               [ ] Yes

 

Signature……………..................................................... Date………………………..

 

Notes

If you have declared an interest on this form, a note of this will be made underneath your abstract or presentation title in the CD-ROM and programme.

If you have declared an interest on this form, you are required to make a brief oral declaration and/or display a slide to this effect at the beginning of your presentation.

Please return this declaration to the Congress Organizing Committee.